Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) announced that on May 1, 2026 the Compensation Committee granted restricted stock units totaling 188,000 shares to five new employees under the 2023 Inducement Plan as an inducement under Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date and are subject to each employee's continued service through each vesting date.

News Market Reaction – TSHA

+4.90%

+4.90% Session close to close

In the May 4 session, TSHA gained 4.90%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement reflects a routine equity inducement, with 188,000 RSU shares granted to five new ...

Analysis

This announcement reflects a routine equity inducement, with 188,000 RSU shares granted to five new employees under the 2023 Inducement Plan, vesting over four years. It continues Taysha’s use of Nasdaq Listing Rule 5635(c)(4) for hiring, similar to the March inducement grant. In context, more material recent developments have included full‑year 2025 results, Rett syndrome trial progress, and a cash runway into 2028, which are likely to remain the primary fundamental drivers.

Key Figures

RSU shares granted: 188,000 shares Number of employees: 5 employees Vesting schedule: 4 annual installments +2 more

5 metrics

RSU shares granted 188,000 shares Aggregate RSUs to five new employees under 2023 Inducement Plan

Number of employees 5 employees Recipients of inducement RSU awards

Vesting schedule 4 annual installments RSUs vest in four equal annual installments from first anniversary

Listing rule Nasdaq Rule 5635(c)(4) Inducement awards granted in accordance with Nasdaq listing rule

Inducement plan year 2023 Taysha Gene Therapies, Inc. 2023 Inducement Plan

Historical Context

5 past events · Latest: Apr 29 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 29	Earnings call scheduling	Neutral	-0.5%	Set date and time for Q1 2026 financial results call and webcast.
Apr 27	Preclinical data update	Positive	-2.5%	New ASGCT data supporting TSHA-102 construct design and CNS delivery approach.
Mar 19	Earnings and pipeline	Positive	+2.5%	Full-year 2025 results plus Rett trial progress and extended cash runway.
Mar 12	Earnings call scheduling	Neutral	+2.1%	Announcement of date and access details for full-year 2025 results call.
Mar 06	Inducement equity grant	Neutral	+1.8%	RSU and option inducement awards to new employees under 2023 plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent TSHA news has mostly seen price moves align with the nature of the announcements, with one notable divergence on positive preclinical data.

Recent Company History

Over the past six months, Taysha has alternated between clinical, financial, and administrative updates. A March 19, 2026 full‑year 2025 report with Rett syndrome progress and a cash runway into 2028 saw a 2.47% gain. Conference‑call scheduling releases on March 12 and April 29 led to modest moves of +2.10% and -0.48%. A prior inducement grant on March 6 coincided with a 1.78% rise. Only the April 27 positive preclinical TSHA‑102 data showed a -2.48% divergence.

Key Terms

restricted stock units (rsus), nasdaq listing rule 5635(c)(4), adeno-associated virus (aav), central nervous system (cns)

4 terms

restricted stock units (rsus) financial

"granted five new employees, in the aggregate, restricted stock units (RSUs) representing"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

adeno-associated virus (aav) medical

"advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic"

Adeno-associated virus (AAV) is a small, naturally occurring virus repurposed as a delivery vehicle to carry corrective genes into human cells for gene therapy. Think of it as a microscopic delivery truck that transports instructions to fix broken cellular machinery. Investors care because AAVs drive the safety, effectiveness, manufacturing difficulty and regulatory review of gene therapies, and those factors strongly influence development costs, approval timelines and commercial value.

central nervous system (cns) medical

"severe monogenic diseases of the central nervous system (CNS), today announced that"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, May 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, restricted stock units (RSUs) representing 188,000 shares of the Company’s common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

FAQ

What did Taysha (TSHA) announce on May 1, 2026 about employee equity?

Taysha granted 188,000 RSUs to five new employees as an inducement under Nasdaq rules. According to the company, the awards were made under the 2023 Inducement Plan and tied to new hires to support retention.

How do the RSUs granted by Taysha (TSHA) vest and when do they start vesting?

The RSUs vest in four equal annual installments, starting on the first anniversary of the vesting commencement date. According to the company, vesting is conditioned on each employee's continued service through each vesting date.

Why did Taysha (TSHA) use an inducement grant under Nasdaq Listing Rule 5635(c)(4)?

Taysha used an inducement grant to provide equity incentives for new hires in compliance with Nasdaq Listing Rule 5635(c)(4). According to the company, the RSUs were material inducements to the individuals entering employment.

How many employees received RSUs in Taysha's May 1, 2026 grant and what is the aggregate amount?

Five new employees received RSUs totaling 188,000 shares in the aggregate. According to the company, the grants were issued by the Compensation Committee under the 2023 Inducement Plan.

Will Taysha (TSHA) investors face immediate dilution from the 188,000 RSU grant?

The announcement reports an aggregate grant of 188,000 RSUs, but does not state immediate share issuance or the percentage dilution. According to the company, the awards are RSUs that vest over four years subject to service.